Notice of Results

MaxCyte, Inc.

10 July 2024

 

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

ROCKVILLE, MD, July 10, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, announces that it will release financial results for the second quarter 2024 after the U.S. market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Earnings Conference Call Details

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

MaxCyte Contacts: 

US IR Adviser 

Gilmartin Group 

David Deuchler, CFA 

[phone] 

[e-mail]  

US Media Relations 

Spectrum Seismic Collaborative 

Valerie Enes 

[phone] 

[e-mail] 

Nominated Adviser and Joint Corporate Broker 

Panmure Liberum

Emma Earl / Freddy Crossley 

Corporate Broking 

Rupert Dearden 

[phone] 

UK IR Adviser 

ICR Consilium

Mary-Jane Elliott 

Chris Welsh 

[phone]

[e-mail] 

 

END